EUVIMEDOpdag EUVIMED
Crossref

A Phase 1 Prognostic Trial for Predicting Paediatric Allergy Using the Placenta at Birth

Vicki L Clifton iD, Zarqa Saif iD, Ana Patricia Balbon iD, Muhammad Afnan iD, Andrew Tai iD, Sailesh Kumar iD, Janet M Davies iD, Peter D Sly iD, Jane Peake iD, Richard Saffery iD, Peter J Vuillermin iD, BIS Investigator Group and 1 more

Clinical & Experimental Allergy · 2026-07 · 56 (7) · 748-757

DOI: 10.1111/cea.70272 ↗

At a glance

Journal article in Clinical & Experimental Allergy, published online on 2026-03-07. Written by Vicki L Clifton and 12 co-authors. Institution: Mater Research Institute, The University of Queensland, Brisbane, Australia. Major MEDLINE topics: Hypersensitivity, Placenta. 30 references. Funded by: National Health and Medical Research Council, Mater Foundation, University of Adelaide.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Allergy is the most common and earliest onset non‐communicable disease in children. The early identification of children who are at risk of allergy would allow early intervention to prevent the onset of the disease or reduce its impact. The origins of allergy are hypothesized to be derived from early developmental events which include prenatal events and early childhood exposures. We have previously identified that many placental glucocorticoid‐regulated genes were also associated with child allergy.

Objective

We have questioned if it is possible to predict which children are at risk of allergy based on their placental glucocorticoid‐regulated mRNA profile.

Methods

Placentae from two different populations located in South Australia ( n = 105) and Victoria, Australia ( n = 261) were included in the study. Glucocorticoid regulated genes were measured by qPCR. Statistical modelling was executed in R (version 4.4.1).

Results

Evaluation of the importance of each gene in the model identified AFF1 , ARID5B , IER3 , ATF4 and SLC19A2 as the top five ranking genes. The best‐performing random forest model achieved an AUC of 0.664, indicating moderate ability to distinguish between positive and negative allergic susceptibility. While our models demonstrate both measurable specificity and sensitivity, the glucocorticoid genes particularly excel at identifying children who will not develop an allergy.

Conclusion

This study demonstrates that placental glucocorticoid‐regulated genes possess significant predictive power, especially in identifying individuals unlikely to develop allergies. It offers further evidence that the placentae of nonallergic children and allergic children are transcriptionally distinct.

Subjects

MeSH terms (MEDLINE)

HypersensitivityPlacentaHumansFemalePregnancyChildPrognosisInfant, NewbornMaleGlucocorticoidsChild, PreschoolInfant

Author keywords

allergychildrenclinical trialglucocorticoidsplacenta

Substances

Glucocorticoids

Authors and institutions

  • Mater Research Institute, The University of Queensland, Brisbane, Australia.
  • Department of Physiology, University of Toronto, Toronto, Ontario, Canada.
  • Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada.
  • Paediatric Respiratory and Sleep Medicine, Women's and Children's Hospital, University of Adelaide, Adelaide, South Australia, Australia.
  • School of Biomedical Sciences, Centre for Immunology and Infection Control, Centre for the Environment, Queensland University of Technology, Brisbane, Queensland, Australia.
  • The National Allergy Centre of Excellence, Murdoch Children's Research Institute, Parkville, Victoria, Australia.

ORCID profiles: Vicki L Clifton, Zarqa Saif, Ana Patricia Balbon, Muhammad Afnan, Andrew Tai, Sailesh Kumar, Janet M Davies, Peter D Sly, Jane Peake, Richard Saffery, Peter J Vuillermin, Brian Cox

Funding

  • National Health and Medical Research Council
  • Mater Foundation
  • University of Adelaide

Cite

APA

Clifton, V. L., Saif, Z., Balbon, A. P., Afnan, M., Tai, A., Kumar, S., Davies, J. M., Sly, P. D., Peake, J., Saffery, R., Vuillermin, P. J., BIS Investigator Group, & Cox, B. (2026). A Phase 1 Prognostic Trial for Predicting Paediatric Allergy Using the Placenta at Birth. Clinical & Experimental Allergy, 56(7), 748-757. https://doi.org/10.1111/cea.70272

Vancouver

Clifton VL, Saif Z, Balbon AP, Afnan M, Tai A, Kumar S, et al. A Phase 1 Prognostic Trial for Predicting Paediatric Allergy Using the Placenta at Birth. Clinical & Experimental Allergy. 2026;56(7):748-757. doi:10.1111/cea.70272

BibTeX
@article{Clifton2026,
  author = {Clifton, Vicki L and Saif, Zarqa and Balbon, Ana Patricia and Afnan, Muhammad and Tai, Andrew and Kumar, Sailesh and Davies, Janet M and Sly, Peter D and Peake, Jane and Saffery, Richard and Vuillermin, Peter J and BIS Investigator Group, BIS Investigator Group and Cox, Brian},
  title = {A Phase 1 Prognostic Trial for Predicting Paediatric Allergy Using the Placenta at Birth},
  journal = {Clinical & Experimental Allergy},
  year = {2026},
  volume = {56},
  number = {7},
  pages = {748--757},
  doi = {10.1111/cea.70272}
}
Start for free →